Acerus Pharmaceuticals Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acerus Pharmaceuticals Corporation
Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.
Studies are unfeasible, sponsors argue in advance of US advisory committee meeting that could lead to FDA ending its waiver on requiring clinical trials in pediatric patients for new testosterone replacement therapy products.
Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Trimel BioPharma Holdings Inc.
- Trimel Biopharma SRL
- Trimel Pharmaceuticals Corporation